专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100015101A1 NOVEL TUMOR ANTIGEN PEPTIDES 审中-公开
标题翻译：新型肿瘤抗原肽
公开(公告)号：US20100015101A1
公开(公告)日：2010-01-21
申请号：US12294899
申请日：2007-03-27
申请人： Noriyuki Sato , Toshihiko Torigoe , Yoshihiko Hirohashi , Kenji Harada
发明人： Noriyuki Sato , Toshihiko Torigoe , Yoshihiko Hirohashi , Kenji Harada
IPC分类号： A61K35/12 , C12N9/10 , A61K38/45 , C07H21/04 , A61K31/7088 , C12N5/02 , C07K16/00 , C12Q1/48 , A61P35/04 , C12Q1/68
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/5158 , A61K2039/57 , C07K16/30 , C07K16/40 , C12Q1/6886 , C12Q2600/158 , G01N33/574 , G01N33/57407
摘要： The invention relates to novel tumor antigen proteins and peptides derived therefrom and use of the same in the filed of cancer immunity. Specifically, the inventions relates to a peptide which comprises a partial peptide derived from Lengsin, BJ-TSA-9, C20orf42, BUB1, C10orf3 or HIFPH3 and is capable of binding to an HLA antigen and is recognized by a CTL, and a pharmaceutical composition comprising the peptide and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及新的肿瘤抗原蛋白及其衍生的肽及其在癌症免疫领域中的用途。具体地，本发明涉及包含衍生自Lengsin，BJ-TSA-9，C20orf42，BUB1，C10orf3或HIFPH3的部分肽并且能够结合HLA抗原并被CTL识别的肽和药物组合物包括肽和药学上可接受的载体。

2. 发明申请

US20100034780A1 TUMOR ANTIGEN PEPTIDE DERIVED FROM AMACR 审中-公开
标题翻译：从AMACR衍生的肿瘤抗原肽
公开(公告)号：US20100034780A1
公开(公告)日：2010-02-11
申请号：US12096572
申请日：2006-06-27
申请人： Noriyuki Sato , Toshihiko Torigoe , Ichiya Honma , Yoshihiko Hirohashi , Kenji Harada
发明人： Noriyuki Sato , Toshihiko Torigoe , Ichiya Honma , Yoshihiko Hirohashi , Kenji Harada
IPC分类号： A61K38/43 , A61K35/00 , C12N9/00 , C12N5/0784 , C12N5/0783 , C12N5/00 , A61K48/00 , C07K16/40 , C07H21/00
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00 , G01N33/57434 , G01N2333/99 , G01N2800/52
摘要： The present invention relates to a peptide which comprises a partial peptide derived from AMACR and is capable of binding to an HLA antigen and is recognized by a CTL, and a pharmaceutical composition comprising the peptide and a pharmaceutically acceptable carrier, and the like.
摘要翻译：本发明涉及一种肽，其包含衍生自AMACR的部分肽并且能够结合HLA抗原并被CTL识别，以及包含该肽和药学上可接受的载体的药物组合物等。

3. 发明授权

US07601801B2 HLA-A24 binding cancer antigen peptide derived from livin 失效
标题翻译：来自livin的HLA-A24结合癌抗原肽
公开(公告)号：US07601801B2
公开(公告)日：2009-10-13
申请号：US10563916
申请日：2004-07-07
申请人： Noriyuki Sato , Toshihiko Torigoe , Hiroyuki Hariu , Yoshihiko Hirohashi
发明人： Noriyuki Sato , Toshihiko Torigoe , Hiroyuki Hariu , Yoshihiko Hirohashi
IPC分类号： C07K16/00 , A61K38/00
CPC分类号： C07K7/06 , A61K38/1709 , A61K39/0011 , A61K2039/53 , A61K2039/572 , C07K14/4702 , C07K16/2833
摘要： The present invention provides a partial peptide consisting of 8-11 contiguous amino acids in the amino acid sequence of livin set forth in SEQ ID NO: 1, which binds to HLA-A24 antigen and is recognized by cytotoxic T cells (CTLs), a polynucleotide encoding the peptide, and cancer vaccine comprising the peptide or the polynucleotide.
摘要翻译：本发明提供由SEQ ID NO：1所示的livin氨基酸序列中的8-11个连续氨基酸组成的部分肽，其结合HLA-A24抗原并被细胞毒性T细胞（CTLs）识别，编码该肽的多核苷酸，以及包含该肽或该多核苷酸的癌症疫苗。

4. 发明申请

US20070036812A1 Hla-a24 binding cancer antigen peptide derived from livin 失效
标题翻译：来自livin的Hla-a24结合癌抗原肽
公开(公告)号：US20070036812A1
公开(公告)日：2007-02-15
申请号：US10563916
申请日：2004-07-07
申请人： Noriyuki Sato , Toshihiki Torigoe , Hiroyuki Hariu , Yoshihiko Hirohashi
发明人： Noriyuki Sato , Toshihiki Torigoe , Hiroyuki Hariu , Yoshihiko Hirohashi
IPC分类号： G01N33/574 , C07H21/04 , C12P21/06 , A61K39/00 , C07K7/08 , C07K14/74
CPC分类号： C07K7/06 , A61K38/1709 , A61K39/0011 , A61K2039/53 , A61K2039/572 , C07K14/4702 , C07K16/2833
摘要： The present invention provides a partial peptide consisting of 8-11 contiguous amino acids in the amino acid sequence of livin set forth in SEQ ID NO: 1, which binds to HLA-A24 antigen and is recognized by cytotoxic T cells (CTLs), a polynucleotide encoding the peptide, and cancer vaccine comprising the peptide or the polynucleotide.
摘要翻译：本发明提供由SEQ ID NO：1所示的livin氨基酸序列中的8-11个连续氨基酸组成的部分肽，其结合HLA-A24抗原并被细胞毒性T细胞（CTLs）识别，编码该肽的多核苷酸，以及包含该肽或该多核苷酸的癌症疫苗。

5. 发明申请

US20100093862A1 POTENTIATION OF CELLULAR IMMUNITY USING HISTONE DEACETYLASE (HDAC) INHIBITORS. 审中-公开
标题翻译：使用HISTONE脱乙酰壳多糖（HDAC）抑制剂的细胞免疫的潜能。
公开(公告)号：US20100093862A1
公开(公告)日：2010-04-15
申请号：US12448073
申请日：2007-12-06
申请人： Toshihiko Torigoe , Noriyuki Sato , Hiroko Asanuma , Nobuhiro Fujii , Masaho Ishino
发明人： Toshihiko Torigoe , Noriyuki Sato , Hiroko Asanuma , Nobuhiro Fujii , Masaho Ishino
IPC分类号： A61K31/19 , C07C53/126 , C12Q1/68 , C12Q1/02 , A61P37/04 , A61P31/00 , A61P35/00
CPC分类号： A61K31/19 , G01N33/6893 , G01N2333/70539 , G01N2333/916 , Y02A50/463
摘要： [Technical Problem] The present invention provides an enhancer of cellular immunity, and provides applications to carcinogenesis or preventive therapy against cancer recurrence, immunotherapy for cancer, treatment for pathogenic microorganism infection, and the like.[Technical Solution] The present invention comprises the substance having an inhibitory activity of histone deacetylase (HDAC) as an active component.
摘要翻译：技术问题本发明提供细胞免疫的增强剂，提供癌症复发，癌症免疫治疗，病原微生物感染治疗等的癌发生或预防疗法的应用。技术方案本发明包含具有组蛋白脱乙酰酶（HDAC）作为活性成分的抑制活性的物质。

6. 发明申请

US20090275055A1 Monoclonal Antibodies Specific to Denatured Human Class I Leucocyte Antigens 审中-公开
标题翻译：特异于人类I类白细胞抗原的单克隆抗体
公开(公告)号：US20090275055A1
公开(公告)日：2009-11-05
申请号：US11887297
申请日：2006-03-27
申请人： Noriyuki Sato , Toshihiko Torigoe , Kumiko Shimozawa , Emiri Nakazawa
发明人： Noriyuki Sato , Toshihiko Torigoe , Kumiko Shimozawa , Emiri Nakazawa
IPC分类号： G01N33/567 , C07K16/28 , C12N5/16 , C07H21/04
CPC分类号： G01N33/574 , C07K16/2833 , G01N33/5082 , G01N33/56977 , G01N33/577
摘要： [PROBLEMS] To provide a monoclonal antibody simultaneously detectable the expression of all three kinds of HLA-A, HLA-B and HLA-C heavy chain proteins composing human class I leukocyte antigens (HLA class I) in denatured human tissue samples fixed by formalin and the like.[MEANS FOR SOLVING THE PROBLEMS] It was discovered that injection of denatured recombinant HILA-A*2402 heavy chain proteins to mouse for immunization led to establish HLA class I-specific antibody binding all of denatured HLA-A, B and C. The present invention is a monoclonal antibody specifically binding HLA-A, HLA-B and HLA-C heavy chains composing denatured human class I antigens, wherein said monoclonal antibody is produced by hybridomas (FERM AP-20454) and bound specifically HLA-A, HLA-B and HLA-C heavy chains composing denatured human class I antigens. Furthermore, the present invention is a test reagent for examining denatured human class I leukocyte antigens containing the monoclonal antibody as a major component.
摘要翻译： [问题]提供单克隆抗体同时检测构成人类I类白细胞抗原（HLA I类）的所有三种HLA-A，HLA-B和HLA-C重链蛋白在由福尔马林固定的变性人体组织样品中的表达等等。 [解决问题的手段]发现将变性重组HILA-A * 2402重链蛋白注射到小鼠进行免疫导致建立HLA I类特异性抗体，其结合所有变性的HLA-A，B和C。本发明本发明是特异性结合构成变性人I类抗原的HLA-A，HLA-B和HLA-C重链的单克隆抗体，其中所述单克隆抗体由杂交瘤（FERM AP-20454）产生并特异性结合HLA-A，HLA- B和构成变性人I类抗原的HLA-C重链。此外，本发明是用于检测含有单克隆抗体作为主要成分的变性人I类白细胞抗原的试剂。

7. 发明授权

US06444800B1 Human gastric cancer antigen gene and gastric cancer antigen protein 失效
公开(公告)号：US06444800B1
公开(公告)日：2002-09-03
申请号：US09348265
申请日：1999-07-07
申请人： Kokichi Kikuchi , Noriyuki Sato , Toshihiko Torigoe , Hiroeki Sahara , Manabu Suzuki , Junji Hamuro
发明人： Kokichi Kikuchi , Noriyuki Sato , Toshihiko Torigoe , Hiroeki Sahara , Manabu Suzuki , Junji Hamuro
IPC分类号： C07H2102
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00
摘要： A tumor antigen gene is identified by screening a cDNA library derived from a gastric cancer cell line that can induce gastric cancer antigen specific cytotoxic T cell (CTL) by means of hybridization and PCR utilizing an amino acid sequence of peptide fragment of a known gastric cancer antigen protein, introducing a selected cDNA clone into a cell of gastric cancer cell line that cannot induce gastric cancer antigen specific CTL so that the clone should be expressed in the cell, and selecting a transgenic cell that has acquired the ability to induce CTL. According to the present invention, there are provided a protein capable of inducing immune response against human gastric cancer, DNA encoding the protein, as well as vaccine for treatment and prevention of human gastric cancer, and agent for treatment and prevention of human gastric cancer.

8. 发明授权

US07030222B2 Human gastric cancer antigen gene and gastric cancer antigen protein 失效
公开(公告)号：US07030222B2
公开(公告)日：2006-04-18
申请号：US10191322
申请日：2002-07-10
申请人： Kokichi Kikuchi , Noriyuki Sato , Toshihiko Torigoe , Hiroeki Sahara , Manabu Suzuki , Junji Hamuro
发明人： Kokichi Kikuchi , Noriyuki Sato , Toshihiko Torigoe , Hiroeki Sahara , Manabu Suzuki , Junji Hamuro
IPC分类号： C07K5/00
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00
摘要： A tumor antigen gene is identified by screening a cDNA library derived from a gastric cancer cell line that can induce gastric cancer antigen specific cytotoxic T cell (CTL) by means of hybridization and PCR utilizing an amino acid sequence of peptide fragment of a known gastric cancer antigen protein, introducing a selected cDNA clone into a cell of gastric cancer cell line that cannot induce gastric cancer antigen specific CTL so that the clone should be expressed in the cell, and selecting a transgenic cell that has acquired the ability to induce CTL. According to the present invention, there are provided a protein capable of inducing immune response against human gastric cancer, DNA encoding the protein, as well as vaccine for treatment and prevention of human gastric cancer, and agent for treatment and prevention of human gastric cancer.

9. 发明授权

US07880994B2 Vibration detection for data storage device and write processing method for data storage device 失效
标题翻译：数据存储装置的振动检测和数据存储装置的写入处理方法
公开(公告)号：US07880994B2
公开(公告)日：2011-02-01
申请号：US12259873
申请日：2008-10-28
申请人： Noriyuki Sato
发明人： Noriyuki Sato
IPC分类号： G11B5/09 , G11B27/36
CPC分类号： G11B20/18 , G11B20/10527 , G11B2020/10759 , G11B2020/183 , G11B2220/2516
摘要： In a data storage device, a head writes data so as to protect data from off track writing to adjust tracks. A control unit acquires large ring buffer during sequential writing and performs a retry to return adjacent tracks, according to data of a return sector area of the ring buffer when a write error occurs. A write error due to a detection mistake of an off track error can be prevented.
摘要翻译：在数据存储装置中，头部写入数据以保护数据不被偏离轨迹写入以调整轨迹。控制单元在顺序写入期间获取大环形缓冲器，并且当发生写入错误时，根据环形缓冲器的返回扇区区域的数据执行重试以返回相邻轨道。可以防止由于偏离磁道错误的检测错误而导致的写入错误。

10. 发明申请

US20090237825A1 STORAGE DEVICE AND CONTROL METHOD THEREOF 审中-公开
标题翻译：存储设备及其控制方法
公开(公告)号：US20090237825A1
公开(公告)日：2009-09-24
申请号：US12402173
申请日：2009-03-11
申请人： Noriyuki Sato , Hideaki Tanaka
发明人： Noriyuki Sato , Hideaki Tanaka
IPC分类号： G11B20/10
CPC分类号： G11B20/10 , G11B19/044 , G11B2020/00079 , G11B2020/10916 , G11B2020/10981
摘要： A storage device includes an access counter that counts the number of track changes or the number of accessed sectors in accessing the recording medium, an access judgment unit that judges whether the recording medium is accessed successively by a host, a count judgment unit that judges whether the count counted by the access counter has reached a predefined number of times when the access judgment unit judges that the recording medium is accessed successively, and an access delay unit. The access delay unit delays the access to the recording medium so that a transfer rate between the storage device and the host is adjusted to a predefined transfer rate when the count judgment unit judges that the number of the count has reached the predefined number of times.
摘要翻译：存储装置包括访问计数器，其对访问记录介质的轨道变化次数或访问扇区数进行计数;访问判断单元，判断记录介质是否被主机连续访问;计数判断单元，判断是否由访问计数器计数的计数器已经达到预定次数，当访问判断单元判断连续访问记录介质时，访问延迟单元。访问延迟单元延迟对记录介质的访问，使得当计数判断单元判断计数的数量已经达到预定次数时，存储设备和主机之间的传送速率被调整到预定的传送速率。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式